Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On January 5, 2023, Apellis Pharmaceuticals, Inc., a Delaware corporation (the "Company"), announced that Federico Grossi, M.D., Ph.D., the Chief Medical Officer of the Company, will be leaving the Company to pursue new career opportunities. In connection with the announcement of Dr. Grossi's departure, the Company also announced that Caroline Baumal, M.D. will join the Company as Chief Medical Officer, effective as of January 3, 2023. Dr. Grossi will cease to serve as Chief Medical Officer effective as of January 3, 2023 and will continue at the Company until February 28, 2023 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses